Latest news
25 items- SECAthersys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ATHERSYS, INC / NEW (0001368148) (Filer)
- SECSEC Form 25-NSE filed by Athersys Inc.25-NSE - ATHERSYS, INC / NEW (0001368148) (Subject)
- SECAthersys Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update8-K - ATHERSYS, INC / NEW (0001368148) (Filer)
- INSIDERHansen Maia covered exercise/tax liability with 67 shares, decreasing direct ownership by 0.10% to 70,010 units (SEC Form 4)4 - ATHERSYS, INC / NEW (0001368148) (Issuer)
- SECSEC Form 424B3 filed by Athersys Inc.424B3 - ATHERSYS, INC / NEW (0001368148) (Filer)
- SECSEC Form EFFECT filed by Athersys Inc.EFFECT - ATHERSYS, INC / NEW (0001368148) (Filer)
- SECSEC Form S-1/A filed by Athersys Inc. (Amendment)S-1/A - ATHERSYS, INC / NEW (0001368148) (Filer)
- NEWSAthersys Q3 EPS $(0.15)
- SECSEC Form 10-Q filed by Athersys Inc.10-Q - ATHERSYS, INC / NEW (0001368148) (Filer)
- PRAthersys Reports Third Quarter 2023 Financial Results and Business HighlightsAthersys, Inc. (OTC:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and Recent Corporate and Operational Highlights: Announced results of a blinded interim analysis of Phase 3 MASTERS-2 clinical trial studying MultiStem for treatment of ischemic stroke indicating additional patients would need to be added to the trial to achieve statistical significance with a primary endpoint of mRS Shift Analysis at Day 365. Completed warrant exercise inducement generating gross proceeds of $3.
- SECSEC Form S-1 filed by Athersys Inc.S-1 - ATHERSYS, INC / NEW (0001368148) (Filer)
- SECAthersys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - ATHERSYS, INC / NEW (0001368148) (Filer)
- SECAthersys Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events8-K - ATHERSYS, INC / NEW (0001368148) (Filer)
- NEWS12 Health Care Stocks Moving In Tuesday's After-Market SessionGainers Biocept (NASDAQ:BIOC) shares moved upwards by 109.4% to $1.07 during Tuesday's after-market session. Trading volume for this security closed at 4.8 million, accounting for 264.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.8 million. Intelligent Bio Solutions (NASDAQ:INBS) shares moved upwards by 31.44% to $0.4. At the close, Intelligent Bio Solutions's trading volume reached 2.0 million shares. This is 1402.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $1.8 million. RVL Pharmaceuticals (NASDAQ:RVLP) stock rose 17.45% to $0.06. RVL Pharmaceuticals's trading volume
- NEWSWhy ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionGainers SciSparc Ltd. (NASDAQ:SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc. Assembly Biosciences, Inc. (NASDAQ:ASMB) gained 120% to $1.5982 after the company and Gilead announced they entered into a 12-year partnership to advance the research and development of novel antiviral therapies. Olink Holding AB (NASDAQ:OLK) shares climbed 65.8% to $24.84 after Thermo Fisher Scientific announced it will acquire the company. MoneyHero Limited (NASDAQ:MNY) surged 33.7% to $3.40. OpGen, Inc. (NASDAQ:OPGN) gained 32.7% to $1.20. FLJ Group Limited (NASDAQ:FLJ) jumped 29.3% to $0.2689. Anebulo Phar
- NEWS12 Health Care Stocks Moving In Tuesday's Pre-Market SessionGainers Assembly Biosciences (NASDAQ:ASMB) shares increased by 108.0% to $1.51 during Tuesday's pre-market session. The company's market cap stands at $79.4 million. Olink Holding (NASDAQ:OLK) stock moved upwards by 67.22% to $25.05. The market value of their outstanding shares is at $3.1 billion. Athersys (NASDAQ:ATHX) shares moved upwards by 33.84% to $0.13. The market value of their outstanding shares is at $3.5 million. Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 16.58% to $5.83. The company's market cap stands at $289.4 million. Akso Health Group (NASDAQ:AHG) shares rose 16.21% to $2.15. The company's market cap stands at $49.1 million. Vigil Neuroscience (NASDAQ:VIGL) shares
- NEWSWhy Vistagen Therapeutics Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving PremarketGainers SciSparc Ltd. (NASDAQ:SPRC) shares surged 79.5% to $5.08 in pre-market trading after falling around 7% on Monday. SciSparc recently regained compliance with the Nasdaq Minimum Bid Price Notification. WiSA Technologies, Inc. (NASDAQ:WISA) shares rose 76.4% to $0.4380 in pre-market trading after falling 40% on Monday. WiSA Technologies announced the pricing of a $4.8 million public offering of Series B convertible redeemable preferred stock and warrants. Athersys, Inc. (NASDAQ:ATHX) shares gained 51.5% to $0.1487 in pre-market trading. Athersys extended near-term liquidity with proceeds from warrant inducement and a global ARDS license with Healios to explore strategic alternati
- NEWSAthersys Warrant Exercise Inducement Offer Letter To Raise Gross Proceeds Of Up To ~$3.9M From The Exercise Of 28,124,590 Warrants And Received The First Tranche Payment Of $1.5M From Healios K.K. Under The ARDS Global License
- NEWSAthersys Extends Near Term Liquidity with Proceeds From Warrant Inducement And Global ARDS License With Healios To Explore Strategic AlternativesAthersys, Inc. (NASDAQ:ATHX), ("Athersys" or the "Company") a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K. ("Healios") under the acute respiratory distress syndrome ("ARDS") global license.On October 11, 2023, Athersys entered into a warrant exercise inducement offer letter (the "Inducement Letter") with a holder of certain existing warrants ("Holder") to receive new warrants to
- PRAthersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic AlternativesAthersys, Inc. (NASDAQ:ATHX), ("Athersys" or the "Company") a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K. ("Healios") under the acute respiratory distress syndrome ("ARDS") global license. On October 11, 2023, Athersys entered into a warrant exercise inducement offer letter (the "Inducement Letter") with a holder of certain existing warrants ("Holder") to receive new warrants
- SECAthersys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - ATHERSYS, INC / NEW (0001368148) (Filer)
- NEWSWhy Astra Space Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionGainers Tempest Therapeutics, Inc. (NASDAQ:TPST) shares jumped 1067% to $2.80 after the company released new data demonstrating superiority of TPST-1120 arm across multiple study endpoints in first-line hepatocellular carcinoma study. Phio Pharmaceuticals Corp. (NASDAQ:PHIO) jumped 59.5% to $2.17. Phio Pharmaceuticals presented new data for targeting of BRD4 with its INTASYL™ compound PH-894. Tupperware Brands Corporation (NYSE:TUP) surged 42.5% to $2.14. Wheeler Real Estate Investment Trust, Inc. (NASDAQ:WHLR) gained 41.4% to $1.2586 after falling 7% on Tuesday. ReTo Eco-Solutions, Inc. (NASDAQ:RETO) jumped 37.3% to $0.7461. Gaucho Group Holdings, Inc. (NASDAQ:VINO) shares climbed 3
- SECAthersys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - ATHERSYS, INC / NEW (0001368148) (Filer)
- NEWS12 Health Care Stocks Moving In Wednesday's Pre-Market SessionGainers Tempest Therapeutics (NASDAQ:TPST) shares increased by 692.0% to $1.9 during Wednesday's pre-market session. The company's market cap stands at $25.3 million. SINTX Techs (NASDAQ:SINT) shares increased by 23.63% to $1.01. The company's market cap stands at $4.2 million. Celularity (NASDAQ:CELU) shares rose 21.21% to $0.24. The company's market cap stands at $45.8 million. Athersys (NASDAQ:ATHX) shares rose 15.5% to $0.14. The company's market cap stands at $3.7 million. Phio Pharma (NASDAQ:PHIO) stock increased by 15.17% to $1.6. The company's market cap stands at $3.5 million. Trinity Biotech (NASDAQ:TRIB) stock rose 14.51% to $0.65. The market value of their outstanding share
- NEWSWhy VOXX International Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving PremarketGainers Tempest Therapeutics, Inc. (NASDAQ:TPST) shares rose 279.8% to $0.9115 in pre-market trading, after the company announced it plans to report new and updated data from the global randomized combination study of TPST-1120 in first-line hepatocellular carcinoma in a premarket press release on Oct. 11. Wheeler Real Estate Investment Trust, Inc. (NASDAQ:WHLR) shares gained 211% to $2.77 in pre-market trading after falling 7% on Tuesday. Athersys, Inc. (NASDAQ:ATHX) shares rose 20.7% to $0.14 in pre-market trading, after falling 60% on Tuesday. Athersys said it intends to conduct additional data analysis with independent statisticians because the sample size in the Phase 3 MASTERS-2 is
ATHX FAQ
6 questionsWhat does Athersys Inc. do?
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of...Where does ATHX stock trade?
Athersys Inc. (ATHX) is listed on NASDAQ.What sector and industry is ATHX in?
Athersys Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ATHX?
Athersys Inc. has had 2 recent analyst actions on file. The most recent action was from B of A Securities: Neutral with a $125.00 price target on 2021-11-19. Recent price targets cluster around $125.00.What companies are similar to ATHX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ATHX side-by-side with any of them on Quantisnow.How can I track ATHX on Quantisnow?
Quantisnow aggregates Athersys Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ATHX to receive live email and push alerts on every new disclosure.